The Economic Burden of Atherosclerotic Cardiovascular Disease in Italy

被引:0
|
作者
Mennini, Francesco S. [1 ]
Scortichini, Matteo [1 ]
Colivicchi, Furio [2 ]
Maggioni, Aldo P. [3 ]
Sciattella, Paolo [1 ]
机构
[1] Univ Roma Tor Vergata, Fac Econ, Ctr Econ & Int Studies, Econ Evaluat & Hlth Technol Assessment, Via Columbia 2, I-00133 Rome, Italy
[2] San Filippo Neri Hosp, Div Cardiol, Rome, Italy
[3] ANMCO Res Ctr Heart Care Fdn, Florence, Italy
关键词
STATIN THERAPY; EZETIMIBE; RISK; ASSOCIATION; ADHERENCE; EFFICACY;
D O I
10.1007/s40261-024-01365-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BackgroundAtherosclerotic cardiovascular diseases remain the primary cause of mortality in Italy. Individuals with a history of acute coronary syndrome, peripheral arterial disease, and ischemic stroke/transient ischemic attack face an elevated risk of recurrent major adverse cardiovascular events, including mortality. The population aging, coupled with increasing risk factors such as diabetes mellitus and obesity, exacerbates the disease's economic impact.ObjectivesThis study aims to comprehensively assess the economic burden of atherosclerotic cardiovascular diseases in Italy, specifically focusing on direct healthcare costs.MethodsWe analyzed real-world data from administrative databases in the Marche region and Local Health Unit Umbria 2. The economic burden of patients discharged with acute coronary syndrome, peripheral arterial disease, and ischemic stroke/transient ischemic attack was evaluated, with a focus on direct costs associated with hospitalizations, drugs, and outpatient visits. Results were stratified by age, sex, comorbidities at baseline, and adherence to lipid-lowering therapy and antihypertensive agents.ResultsAnnually, nearly 350,000 patients were hospitalized for peripheral arterial disease, acute coronary syndrome, or ischemic stroke/transient ischemic attack. Direct health costs averaged <euro>7190 per patient over a 2-year follow-up, with hospitalizations accounting for nearly 70% of the total. Male patients incurred significantly higher costs (<euro>7467) than female patients (<euro>6625). Costs correlated positively with age and with the number of baseline comorbidities, with a range from <euro>5259 (0-1 comorbidities) to <euro>17,095 (4+ comorbidities). Costs were significantly lower in adherent subjects (<euro>6813) compared with non-adherent subjects (<euro>7757).ConclusionsThis study provides valuable insights into the economic implications of atherosclerotic cardiovascular diseases in Italy, emphasizing the necessity of a comprehensive approach to preventive measures, optimal medication adherence, and lifestyle modifications to mitigate its impact.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] The economic Burden through Obesity in Italy
    Voelkel, Lukas
    [J]. GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2022, 27 (03):
  • [42] Heart surgery for immigrants in Italy: burden of cardiovascular disease, adherence to treatment and outcomes
    Grimaldi, Antonio
    Vermi, Anna Chiara
    Cammalleri, Valeria
    Castiglioni, Alessandro
    Pappalardo, Federico
    Taramasso, Maurizio
    Baratto, Francesca
    Alfieri, Ottavio
    [J]. JOURNAL OF CARDIOVASCULAR MEDICINE, 2016, 17 (02) : 105 - 112
  • [43] Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review
    Einarson, Thomas R.
    Acs, Annabel
    Ludwig, Craig
    Panton, Ulrik H.
    [J]. VALUE IN HEALTH, 2018, 21 (07) : 881 - 890
  • [44] The global burden of atherosclerotic vascular disease
    Gregg C Fonarow
    [J]. Nature Clinical Practice Cardiovascular Medicine, 2007, 4 : 530 - 531
  • [45] Economic burden of hypercholesterolemia in high risk of cardiovascular disease population in Mexico
    Gasca-Pineda, Ricardo
    Osorio-Hernandez, Mariana
    Mehta, Roopa
    Escobedo-de-la-Pena, Jorge
    Narvaez-Oriani, Carlos A.
    [J]. ARCHIVOS DE CARDIOLOGIA DE MEXICO, 2023, 93 (03): : 328 - 335
  • [46] Economic burden of physical inactivity: healthcare costs associated with cardiovascular disease
    Oldridge, Neil B.
    [J]. EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2008, 15 (02): : 130 - 139
  • [47] Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease
    Dalal, Anand A.
    Shah, Manan
    Lunacsek, Orsolya
    Hanania, Nicola A.
    [J]. RESPIRATORY MEDICINE, 2011, 105 (10) : 1516 - 1522
  • [48] ECONOMIC BURDEN OF CARDIOVASCULAR DISEASE IN TYPE 2 DIABETES: A SYSTEMATIC REVIEW
    Acs, A.
    Ludwig, C.
    Bereza, B. G.
    Einarson, T. R.
    Panton, U. H.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A476 - A477
  • [49] Economic burden of osteoporosis, breast cancer,and cardiovascular disease among women
    Sasser, A
    Birnbaum, HG
    Oster, EF
    Rousculp, M
    [J]. VALUE IN HEALTH, 2003, 6 (03) : 378 - 378
  • [50] THYROMIMETICS FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
    Tancevski, I.
    Patsch, J. R.
    Eller, P.
    [J]. DRUGS OF THE FUTURE, 2010, 35 (09) : 747 - 753